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S.C. Rankin, J.E. Sykes, J. Turnidge, and J.S. Weese
Respiratory tract disease can be associated with primary or secondary bacterial infections in dogs and cats and is a com-
mon reason for use and potential misuse, improper use, and overuse of antimicrobials. There is a lack of comprehensive
treatment guidelines such as those that are available for human medicine. Accordingly, the International Society for Compan-
ion Animal Infectious Diseases convened a Working Group of clinical microbiologists, pharmacologists, and internists to
share experiences, examine scientific data, review clinical trials, and develop these guidelines to assist veterinarians in making
antimicrobial treatment choices for use in the management of bacterial respiratory diseases in dogs and cats.
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This document contains guidelines for the treatmentof bacterial causes of feline upper respiratory tract
disease (URTD), canine infectious respiratory disease
complex (CIRDC; previously known as canine infec-
tious tracheobronchitis or kennel cough complex),
bronchitis, pneumonia, and pyothorax that were final-
ized in 2016 by the Antimicrobial Guidelines Working
Group of the International Society for Companion
Animal Infectious Diseases (www.iscaid.org). During
the development of the guidelines, other veterinary rec-
ommendations on antimicrobial treatment1–4 and corre-
sponding guidelines for human medicine were
evaluated, with consideration of the differences among
species.5,6
The committee unanimously believes that there are
limitations in objective, published information relevant
to the treatment of bacterial respiratory diseases in dogs
and cats. Thus, the Working Group used a modification
of the Delhi method for consensus building in the devel-
opment of these guidelines.7 The Working Group
reviewed the literature and met in person to develop the
initial draft of the guidelines. This was followed by a
number of revisions completed electronically in an
attempt to build consensus with the wording of each
recommendation within the Working Group. The
Working Group recommendations were then provided
to all guidelines committee members who were asked to
independently select whether they agreed, were neutral,
or disagreed with a recommendation. A updated draft
of the document was then completed and provided to 6
experts in the field that were not members of the Work-
ing Group who were asked to rate each recommenda-
tion by means of the same system. For those
recommendations that received any “disagree” votes
from the 17 total reviewers (Working Group and out-
side reviewers), the percentage distribution of all review-
ers and appropriate comments are presented.
As with all guidelines, the antimicrobial use guideli-
nes for the treatment of bacterial respiratory tract infec-
tions in dogs and cats should be interpreted as general
recommendations that are reasonable and appropriate
for the majority of cases. The Working Group acknowl-
edges the variability among cases and these guidelines
should not be considered standards of care that must be
followed in all circumstances. Rather, they should be
considered the basis of decision-making, with the poten-
tial that different or additional approaches might be
required in some cases. Further, although these guideli-
nes are designed as international guidelines that are
appropriate for all regions of the world, the Working
Group realizes that regional differences in antimicrobial
resistance rates, antimicrobial availability, prescribing
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patterns, and restrictions on use of some agents exist.
The user of this document is obligated to be familiar
with local and regional regulations that might restrict
use of certain antimicrobials listed in this document.
Diagnostic and treatment recommendations contained
in these guidelines are largely limited to those relating
to bacterial infection.
Feline Upper Respiratory Tract Disease
Definitions and Causes
Feline upper respiratory tract disease is a syndrome
consisting of clinical signs that can include serous to
mucopurulent ocular and nasal discharges, epistaxis,
sneezing, and conjunctivitis.8–11 Clinical signs can be
acute (≤10 days) or chronic (>10 days). The term “up-
per respiratory infection (URI)” is reserved for cats
with clinical signs of URTD that are directly associated
with one or more of the known pathogenic viral, bacte-
rial, or fungal organisms.
It is believed that the majority of cats with acute clin-
ical signs of URTD have feline herpesvirus 1 (FHV-1)-
or calicivirus (FCV)-associated URI. Some of the cats
with viral infections can develop secondary bacterial
infections.12–15 Staphylococcus spp., Streptococcus spp.,
Pasteurella multocida, Escherichia coli, and anaerobes
are organisms that are commonly cultured from the sur-
face of the upper respiratory mucous membranes from
healthy cats.16,17 However, several bacterial species,
including Chlamydia felis, Bordetella bronchiseptica,
Streptococcus canis, Streptococcus equi subspp. zooepi-
demicus, and Mycoplasma spp., have been isolated or
detected by molecular techniques such as the poly-
merase chain reaction (PCR) from cats with URTD
without the presence of pathogenic viruses, suggesting a
primary role in some cats.16,18–22 The presence of puru-
lent or mucopurulent nasal or ocular discharges might
increase the suspicion that primary or secondary bacte-
rial infection is present, but there is no definite proof of
this association because viral or fungal agents can also
induce mucopurulent discharges.
Diagnosis of Acute Bacterial Upper Respiratory
Infection (≤10 Days Duration)
For cats with signs of URTD of ≤10 days’ duration,
a thorough history should evaluate in particular the
vaccination status, the presence or exposure to other
cats, whether cats are allowed outdoors, contact with a
shelter, kennel or veterinary hospital, health status of
in-contact cats, health status of in-contact humans,
exposure to dogs that might be boarded or have
recently come from a shelter (possible increased risk of
infection by B. bronchiseptica), likelihood of foreign
body contact (including house plants), and a history of
recent stress which is thought to reactivate FHV-1
infection in some cats.17 Careful ocular, oral, and otic
examination to evaluate for other primary problems is
indicated. Thoracic auscultation should be performed to
evaluate for evidence of concurrent lower respiratory
disease. The Working Group recommends that all cats
with suspected bacterial URI be evaluated for the pres-
ence of feline leukemia virus antigen and feline immun-
odeficiency virus antibodies in serum in accordance
with the American Association of Feline Practitioners
Retrovirus Panel Report.23 Although these retroviruses
do not cause respiratory disease directly, both have
been associated with lymphoma (which could cause
URTD) and both can cause immunosuppression that
could predispose to severe viral and bacterial URIs.
Many diagnostic tests could be performed to assess for
evidence of primary or secondary bacterial URI (See the
Diagnosis of Chronic Bacterial Upper Respiratory Infec-
tion (>10 Days of Duration) section). It is the opinion
of the Working Group that there is limited benefit to per-
forming cytology of nasal discharges to diagnose bacte-
rial infection and guide the antimicrobial choice.
If nasal discharges are serous and lack a mucopuru-
lent or purulent component, the Working Group
believes that antimicrobial treatment is not recom-
mended because of the likelihood of uncomplicated
viral infection.
If acute bacterial URI is suspected based on purulent
or mucopurulent discharge, in the absence of evidence of
the cause of URTD based on history and physical exami-
nation findings, the Working Group recommends a per-
iod of observation without immediate use of an
antimicrobial drug. This might vary in duration based on
other clinical findings (See the Treatment of Suspected
Acute Bacterial Upper Respiratory Infection section). In
humans, antimicrobial treatment is recommended only if
clinical signs have not improved after 10 days or have
worsened after 5–7 days.24 A more extensive workup for
an underlying cause can be postponed until after the per-
iod of observation, up to 10 days after the onset of clini-
cal signs if the cat develops chronic URTD.
Aerobic bacterial culture and antimicrobial suscepti-
bility test results from nasal discharges are difficult to
interpret because (1) some pathogenic organisms (eg,
Chlamydia and Mycoplasma) cannot be cultured on
standard laboratory media and (2) positive culture
might not be associated with bacterial infection due to
growth of commensal organisms. Thus, the Working
Group recommends that aerobic bacterial culture and
antimicrobial susceptibility testing not be performed on
nasal secretions collected from cats with acute bacterial
URI.
Results from Mycoplasma spp. culture (or PCR
assay), and molecular diagnostic procedures for FHV-1,
FCV, and C. felis are difficult to interpret in individual
cats. Mycoplasma spp., FHV-1, FCV, and C. felis can
be grown or amplified by molecular assays from both
healthy or diseased cats, and vaccine strains of B. bron-
chiseptica, FHV-1, FCV, and C. felis can be detected by
molecular diagnostic assays for varying periods of time
depending on the vaccine type.25,26 When positive,
molecular diagnostic tests for FCV, FHV-1, or C. felis
might be useful to support a diagnosis of infection in
the presence of suggestive clinical signs and the absence
of a history of recent vaccination. However, if an out-
break of URI is suspected in populations of cats like
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those in shelters, catteries, boarding facilities, or multi-
ple cat households, these assays also might be indicated,
particularly if severe clinical disease is occurring. If pos-
sible, several affected cats should be evaluated to
increase sensitivity and positive predictive value of the
assay results.
Treatment of Suspected Acute Bacterial Upper
Respiratory Infection
Some cats with mucopurulent nasal discharge main-
tain normal appetite and attitude and experience spon-
taneous resolution of illness within 10 days without
antimicrobial treatment. The Working Group recom-
mends that antimicrobial treatment be considered
within the 10-day observation period only if fever,
lethargy, or anorexia is present concurrently with
mucopurulent nasal discharge.
If antimicrobial treatment is chosen for a cat with
acute bacterial URI, the optimal duration of treatment
is unknown and so this recommendation is based on
experiences of the Working Group members that are
clinicians. The Working Group recommends empirical
administration of doxycycline (Tables 1 and 2) for 7–
10 days to cats with suspected acute bacterial URI as
the first-line antimicrobial option.27,28 The Working
Group believes that doxycycline is a good first choice
because it is well tolerated by cats; most B. bronchisep-
tica isolates from cats are susceptible to doxycycline
in vitro (by unapproved standards for testing), despite
resistance to other agents such as beta-lactams and
sulfonamides,29–31 and doxycycline is effective in vivo
for the treatment of cats with C. felis infections,27,32–34
and Mycoplasma spp. infections.35 Doxycycline is also
effective for the treatment of a variety of chlamydial
and mycoplasma infections in cats and other
Table 1. First-line antimicrobial options for bacterial respiratory infections in the dog and cat.
Infection Type First-Line Drug Options
Acute bacterial upper respiratory
infection (URI) in cats
Doxycyclinea or amoxicillin per os (PO)
Chronic bacterial URI in cats Doxycycline or amoxicillin PO
Base the choice on C&Sb if available
Canine infectious respiratory disease complex
(bacterial component)
Doxycyclinea or amoxicillin–clavulanate PO
Bacterial bronchitis (dogs or cats) Doxycyclinea PO
Base changes if needed on clinical responses and
C&S if available
Pneumonia in animals with extensive contact with
other animals that have no systemic manifestations
of disease (ie, fever, lethargy, dehydration)
Doxycyclinea PO
Base changes if needed on clinical responses
and C&S if available
Pneumonia with or without clinical evidence of sepsisc Parenteral administration of a fluoroquinoloned and a
penicillin or clindamycine initially
Base oral drug choices to follow on clinical responses
and C&S results if available
Pyothorax (dogs or cats)b Parenteral administration of a fluoroquinoloned and a
penicillin or clindamycine initially combined with
therapeutic lavage initially
Base oral drug choices to follow on clinical responses
and C&S results if available
aMinocycline has been substituted in some situations when doxycycline is unavailable or of greater expense. See Table 2 for dose recom-
mendations.
bCulture and antimicrobial susceptibility testing = C&S.
cFor animals with clinical findings of life-threatening disease, the consensus of the Working Group was to administer dual agent treat-
ment parenterally with the potential for de-escalation of treatment and switch to oral drugs based on clinical responses and culture and
antimicrobial susceptibility testing. See Table 2 for dose differences by route and the text for further recommendations for oral or par-
enteral administration.
dEnrofloxacin is often chosen as there is a veterinary product for parenteral administration and the drug has a wide spectrum against
Gram-negative organisms and Mycoplasma spp. There are other drugs with a wide spectrum against Gram-negative bacteria that can be
substituted based on antimicrobial susceptibility testing or clinician preference. See Table 2 for a discussion of how to administer enrofloxa-
cin and for other drug choices. Enrofloxacin should be administered at ≤5 mg/kg/24 h in cats to lessen risk of retinal degeneration. One
reviewer noted that IV ciprofloxacin could also be used; however, the other reviewers (94%) believed that enrofloxacin should be used as
labeled for veterinary use.
eWhen enrofloxacin or other drugs with Gram-negative activity are administered parenterally to animals with life-threatening disease,
concurrent administration of other parenteral drugs with activity against anaerobes and Gram-positive bacteria is recommended. Common
choices include ampicillin or clindamycin. Which of these drugs to choose will depend on the most likely infectious agent suspected and
historical antimicrobial resistance in the geographical region. For example, Enterococcus spp. and Streptococcus spp. are more likely to be
susceptible to a penicillin, and Toxoplasma gondii and Neospora caninum are more likely to be susceptible to clindamycin. Cephalosporins
are generally not recommended for the treatment of anaerobic infections because of unpredictable activity and lack of evidence for their
efficacy. Please see the text for further discussion of other potential drug choices or combinations.
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Table 2. Antimicrobial treatment options for respiratory tract infections in the dog and cat.
Drug Dose Comments
Amikacin Dogs: 15 mg/kg, IV/IM/SC, q24h
Cats: 10 mg/kg, IV/IM/SC, q24h
Not recommended for routine use but might be useful for the
treatment of multidrug-resistant organisms or if parenteral
enrofloxacin or ciprofloxacin are contraindicated. Potentially
nephrotoxic. Avoid in dehydrated animals and those with renal
insufficiency
Amoxicillin 22 mg/kg, PO, q12h Might be useful for the treatment of secondary bacterial URI
caused by Pasteurella spp. and Streptococcus spp., some
Staphylococcus spp. and many anaerobic bacteria. Ineffective
against beta-lactamase-producing bacteria, most Bordetella
bronchiseptica isolates, all Mycoplasma spp., and Chlamydia felis in
cats. One Working Group member supports the use of amoxicillin
q8h because of the short plasma half-life
Amoxicillin–clavulanate Dogs: 11 mg/kg, PO, q12h
Cats: 12.5 mg/kg, PO, q12h
(dose based on
combination of
amoxicillin–clavulanate
Used as a first-line option for secondary bacterial URI from
Pasteurella spp., Streptococcus spp., methicillin-susceptible
Staphylococcus spp. (including penicillinase-producing strains),
many anaerobic bacteria, and most B. bronchiseptica isolates.
Ineffective against all Mycoplasma spp., and inferior to other drugs
for C. felis in cats. One Working Group member supports the use
of amoxicillin q8h because of the short plasma half-life
Ampicillin-sulbactam 20 mg/kg, IV, IM, q6–8h Used alone parenterally for cases with uncomplicated secondary
bacterial pneumonia (Gram-positive and anaerobic bacteria). Used
concurrently with another drug with wider Gram-negative activity
if life-threatening disease exists
Ampicillin sodium 22–30 mg/kg, IV, SQ, q8h Used parenterally for cases with uncomplicated secondary bacterial
pneumonia (Gram-positive and anaerobic bacteria). Used
concurrently with another drug with Gram-negative activity if life-
threatening disease exists
Azithromycin 5–10 mg/kg, PO, q12h day 1
and then q3 days (Longer
intervals are not indicated)
Used for primary bacterial diseases (in particular Mycoplasma spp.)
and for pneumonia of undetermined etiology because the spectrum
includes Toxoplasma gondii and Neospora caninum
Cefazolin 25 mg/kg, SQ, IM, IV, q6h Used parenterally for cases with uncomplicated secondary bacterial
pneumonia (Gram-positive and anaerobic bacteria). Used
concurrently with another drug with wider Gram-negative activity
if life-threatening disease exists. Ineffective against
B. bronchiseptica, Mycoplasma spp., and C. felis in cats, and
enterococci
Cefadroxil Dogs: 11–22 mg/kg, PO, q12h
Cats: 22 mg/kg, PO, q24h
Used PO for secondary bacterial URI from Pasteurella spp., and
some Staphylococcus spp. and Streptococcus spp., and many
anaerobic bacteria. Ineffective against B. bronchiseptica,
Mycoplasma spp., and C. felis in cats, and Enterococcus spp.
Resistance might be common in Enterobacteriaceae in some regions
Cefoxitin 10–20 mg/kg, IV, IM, q6–8h Used parenterally for cases with secondary bacterial pneumonia
(Gram-positive and anaerobic bacteria). Has a greater Gram-
negative spectrum than first-generation cephalosporins. Ineffective
against B. bronchiseptica, Mycoplasma spp., and C. felis in cats,
and Enterococcus spp
Cefovecin 8 mg/kg, SC, once. Can be repeated
once after 7–14 days
Might be effective for the treatment of secondary bacterial URI
caused by Pasteurella spp., some Staphylococcus pseudintermedius
and Streptococcus spp. Ineffective for B. bronchiseptica,
Mycoplasma spp., and C. felis in cats and Enterococcus spp.
Pharmacokinetic data are available to support the use in dogs and
cats, with a duration of 14 days (dogs) and 21 days (cats)
Cephalexin 22–25 mg/kg, PO, q12h See cefadroxil comments
Chloramphenicol Dogs: 50 mg/kg, PO, q8h
Cats: 50 mg/cat, PO q12h
Reserved for multidrug-resistant infections with few other options.
Effective for the primary bacterial pathogens, penetrates tissues
well, and has an excellent spectrum against anaerobes and so
might be considered for the treatment of pneumonia when the
owner cannot afford dual antimicrobial agent treatment.
Myelosuppression can occur, particularly with long-term treatment.
Owners should be instructed to wear gloves when handling the
drug because of rare idiosyncratic aplastic anemia in humans
(continued)
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Table 2 (Continued)
Drug Dose Comments
Clindamycin Dogs: 10 mg/kg, PO, SC, q12h
Cats: 10–15 mg/kg, PO, SC, q12h
Activity against most anaerobic bacteria, many Gram-positive
bacteria and some mycoplasmas. Not effective for most Gram-
negative bacteria and some Bacterioides spp.
Doxycycline 5 mg/kg, PO, q12h
Or
10 mg/kg, PO, q24h
Used for dogs or cats with URI, CIRDC, or bronchitis that is likely
to be associated with B. bronchiseptica, Mycoplasma spp., and
C. felis (cats). An injectable formulation is available if parenteral
administration is needed. Either the hyclate or monohydrate salts
can be used. Can be used in kittens and puppies >4 weeks of age
without enamel discoloration
Enrofloxacin Dogs: 5–20 mg/kg PO, IM, IV q24h
Cats: 5 mg/kg, PO, q24h
Active against most isolates of B. bronchiseptica, Mycoplasma spp.,
and C. felis (cats) as well as many secondary Gram-negative and
Gram-positive bacteria. Practically no activity against Enterococcus
spp and anaerobic bacteria. Associated with risk of retinopathy in
cats and so do not exceed 5 mg/kg/d of enrofloxacin in this
species. All quinolones are associated with cartilage problems in
growing puppies and kittens. Enrofloxacin is not approved for
parenteral use in cats and is not soluble enough to be injected
directly. It can precipitate and can chelate with cations in some
fluid solutions. One Working Group member recommends never
with the 5 mg/kg dose in dogs because of likely induction of
resistant strains and 1 Working Group member does not
recommend the drug for cats because the 5 mg/kg dose might
induce resistance and higher doses can induce retinal degeneration
Gentamicin Dogs: 9–14 mg/kg, IV, q24h
Cats: 5–8 mg/kg, IV, q24h
Not recommended for routine use but might be useful for the
treatment of multidrug-resistant organisms or if parenteral
enrofloxacin is contraindicated. Potentially nephrotoxic. Avoid in
dehydrated animals and those with renal insufficiency
Imipenem–cilastatin 3–10 mg/kg, IV, IM q8h Reserve for the treatment of multidrug-resistant infections,
particularly those caused by Enterobacteriaceae or Pseudomonas
aeruginosa. Recommend consultation with a respiratory or infectious
disease veterinary specialist or veterinary pharmacologist before use
Marbofloxacin 2.7–5.5 mg/kg PO q24h Effective for the primary bacterial pathogens B. bronchiseptica,
Mycoplasma spp., and C. felis (cats) as well as many secondary
infections with Gram-negative and Gram-positive organisms.
Limited efficacy against Enterococcus spp. and anaerobic bacteria.
Available as an injectable solution in some countries
Meropenem Dogs: 8.5 mg/kg SC q12h
Or 24 mg/kg IV q12h
Cats: 10 mg/kg q12h, SC, IM, IV
Reserve for the treatment of multidrug-resistant infections,
particularly those caused by Enterobacteriaceae or P. aeruginosa.
Recommend consultation with an infectious disease veterinary
specialist or veterinary pharmacologist before use
Minocycline Dogs: 5 mg/kg, PO, q12h
Cats: 8.8 mg/kg PO q24h or
50 mg/cat PO q24h
Similar to doxycycline and can be used for dogs or cats with URI,
CIRDC, or bronchitis that is likely to be associated with
B. bronchiseptica, Mycoplasma spp., and C. felis (cats)
Orbifloxacin 2.5–7.5 mg/kg PO q12h for tablets
7.5 mg/kg, PO, q12h for the oral
suspension in cats
See Marbofloxacin comments. The oral suspension is well tolerated
by cats
Ormetoprim-
sulfadimethoxine
27.5 mg/kg, PO q24h in dogs
Note: dosing is based on total
sulfadimethoxine-ormetoprim
concentration (5 to 1 ratio)
See comments on trimethoprim–sulfonamide-containing products
Pradofloxacin 5.0 mg/kg PO q24h if tablets are
used in dogs or cats
7.5 mg/kg PO q24h if oral
suspension for cats is used
Effective for the primary bacterial pathogens B. bronchiseptica,
Mycoplasma spp., and C. felis (cats) as well as many secondary
infections with Gram-negative and Gram-positive organisms. In
contrast to other veterinary fluoroquinolones, pradofloxacin has
activity against some anaerobic bacteria. The drug is labeled in
some countries for the treatment of acute infections of the upper
respiratory tract of cats caused by susceptible strains of Pasteurella
multocida, Escherichia coli and the S. intermedius group (including
S. pseudintermedius). The use of pradofloxacin in dogs has been
associated with myelosuppression and is extra-label in North
America
(continued)
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mammalian host species. It also has activity against
many opportunistic bacterial pathogens that are compo-
nents of the normal microbiota of the respiratory tract.
Of the 17 reviewers, 16 (94%) agreed with this Working
Group recommendation and 1 disagreed because there
is no breakpoint data for this antimicrobial for B. bron-
chiseptica or other bacteria in cats and there are no
pharmacokinetics, controlled clinical trials, susceptibility
data, or pharmacodynamic data on which to base the
recommendation.
Due to delayed esophageal transit time for capsules
and tablets, cats are prone to drug-induced esophagitis
and resultant esophageal strictures.36,37 Although any
table or capsule could cause this problem, doxycycline
hyclate tablets and clindamycin hydrochloride cap-
sules have been reported most frequently to cause
problems.38–40 Thus, tablets and capsules should be given
coated with a lubricating substance, followed by water,
administered in a pill treat, concurrently with at least
2 mL of a liquid, or followed by a small amount of
food.37 Doxycycline formulated and approved for use in
cats is available in some countries and should be used if
available. The use of compounded suspensions of doxy-
cycline should be avoided because marketing of such for-
mulations is in violation with regulations in some
countries, including the USA. In addition, compounded
aqueous-based formulations of doxycycline are associ-
ated with a variable loss of activity beyond 7 days.41
Minocycline pharmacokinetics are now available for cats
and this tetracycline should be evaluated further for effi-
cacy against infectious disease agents in cats.42
The Working Group considers amoxicillin to be an
acceptable alternate first-line option for the treatment
of acute bacterial URI when C. felis and Mycoplasma
are not highly suspected. This is based on evidence that
cats administered amoxicillin for the treatment of sus-
pected secondary bacterial infections in shelter cats with
acute bacterial URI often have apparent clinical
responses.20,43 Cats administered amoxicillin and
clavulanate potassium (amoxicillin–clavulanate) had
apparent clinical responses in 1 study of shelter cats
with acute bacterial URI and so this drug also could be
considered as an alternative to doxycycline in regions
where a high prevalence of beta-lactamase-producing
organisms has been identified (eg, based on regional
antibiograms).44
In 1 study of shelter cats with suspected bacterial URI,
the injectable cephalosporin, cefovecin was inferior to
doxycycline or amoxicillin–clavulanate.44 One limitation
of this study was the lack of a negative control group.44
Thus, it is the opinion of the Working Group that more
evidence is needed before cefovecin can be recommended
for the treatment of bacterial URI in cats (Table 2).
Monitoring Treatment of Suspected Acute Bacterial
Upper Respiratory Infection
Most cats with this syndrome will rapidly improve
within 10 days with or without antimicrobial adminis-
tration. If an antimicrobial drug was prescribed and
was ineffective and bacterial infection is still suspected
after the first 7–10 days of administration, the Working
Group recommends that a more extensive diagnostic
workup should be offered to the owner. An alternate
antimicrobial agent with a different spectrum should be
considered only if the owner refuses a diagnostic
workup and careful re-evaluation of the cat still sup-
ports the presence of a bacterial infection without an
obvious underlying cause (see the Diagnosis of acute
bacterial Upper Respiratory Infection section). Longer
duration of treatment might be required to clear the
carrier state of C. felis.33,34
Diagnosis of Chronic Bacterial Upper Respiratory
Infection (>10 Days of Duration)
A more extensive diagnostic workup should be con-
sidered for cats with URTD of >10 days of duration,
Table 2 (Continued)
Drug Dose Comments
Piperacillin-tazobactam 50 mg/kg IV q6h for
immunocompetent animals,
or 3.2 mg/kg/h CRI, after loading
dose of 3 mg/kg IV, for other
animals
Antipseudomonal penicillin. Used for life-threatening pneumonia or
pyothorax for the treatment of Gram-negative (including some
ESBL), Gram-positive and anaerobic bacteria. Ineffective for
Mycoplasma, T. gondii, and N. caninum
Trimethoprim-
sulfamethoxazole,
trimethoprim-sulfadiazine
15 mg/kg PO q12h
Note: dosing is based on total
trimethoprim + sulfadiazine
concentration
Generally avoided in respiratory tract infections that might involve
anaerobic bacteria (particularly pyothorax). Might be less effective
that other first-line choices for some primary bacterial pathogens
other than Streptococcus spp. Concerns regarding adverse effects
exist (KCS, folate deficiency anemia, blood dyscrasias) in some
dogs, especially with prolonged treatment. If prolonged (>7 day)
treatment is anticipated, baseline Schirmer’s tear testing is
recommended, with periodic re-evaluation and owner monitoring
for ocular discharge. Avoid in dogs that might be sensitive to
potential adverse effects such as KCS, hepatopathy,
hypersensitivity, and skin eruptions, and owners of treated dogs
should be informed of the clinical findings to be monitored.
CIRDC, canine infectious respiratory disease complex; URI, upper respiratory infection.
6 Lappin et al
particularly in the face of therapeutic failure after treat-
ment of suspected acute bacterial URI as described.
The diagnostic workup should be performed to eval-
uate for other causes including Cuterebra spp. and fun-
gal diseases as well as noninfectious causes of URTD
including allergic diseases, neoplasia, foreign bodies,
nasopharyngeal stenosis, oronasal fistulas, nasopharyn-
geal polyps, and trauma.8–11 Referral to a specialist is
recommended if advanced imaging or rhinoscopy capa-
bilities are not available. If other treatable causes of
URTD are not identified, The Working Group recom-
mends that nasal lavage or brushings (for cytology, aer-
obic bacterial culture and antimicrobial susceptibility
testing, Mycoplasma spp. culture or PCR, and fungal
culture) and nasal tissue biopsy for histopathological
examination with or without cultures (if not evaluated
by lavage) should be performed. Of the 17 reviewers,
16 (94%) agreed with the recommendation and 1 dis-
agreed and stated that the results of nasal tissue cul-
tures in cats with chronic URTD are always impossible
to interpret.
In 1 study, nasal lavage specimens gave a higher
sensitivity for bacterial growth than tissue biopsy
specimens.45 However, as discussed previously, bacterial
culture results can be difficult to impossible to interpret
as bacteria can be cultured from the nasal cavity of
healthy cats. For example, multidrug-resistant bacteria
can colonize and be grown from the nasal passages in
the absence of infection. The purpose of culture and
susceptibility testing in cats with chronic bacterial URI
is usually to identify the antimicrobial susceptibility of
severe secondary bacterial infections that occur sec-
ondary to an untreatable underlying cause (eg, idio-
pathic inflammatory rhinitis). Antimicrobial treatment
of these cats might provide relief from severe clinical
signs, but it should be recognized that these cats will
continue to be predisposed to opportunistic infections,
often with antimicrobial-resistant bacteria. Therefore,
use of antimicrobials should be limited to those cats
with severe clinical signs.
The Working Group recommends consultation with
an internal medicine specialist with expertise in infec-
tious disease, clinical pharmacologist, or clinical micro-
biologist before treating multidrug-resistant organisms
(resistant to ≥3 drug classes) isolated from nasal lavage
cultures.
Treatment of Chronic Feline Bacterial Upper
Respiratory Infection
In cats with chronic bacterial URI, the antimicrobial
agent should be selected on the basis of culture and
antimicrobial susceptibility test results if available. If an
organism with resistance against a previously prescribed
antimicrobial agent is identified and the clinical
response is poor, an alternate drug should be substi-
tuted (Table 2).
Pradofloxacin is a veterinary fluoroquinolone that is
approved in some countries for the treatment of acute
infections of the upper respiratory tract caused by
susceptible strains of P. multocida, E. coli and the
Staphylococcus intermedius group.46 In 1 study of shel-
ter cats, a pradofloxacin protocol was equivalent to
amoxicillin for the treatment of suspected bacterial
URI.20 The other veterinary fluoroquinolones (en-
rofloxacin, orbifloxacin, and marbofloxacin [Table 2])
have also been used by veterinarians to treat suspected
feline bacterial URI.47 In the first study, all cats were
administered an antibiotic;20 a placebo control study
evaluating pradofloxacin for the treatment of bacterial
URI in cats has not been published to our knowledge.
Because of concerns about the emergence of, and ani-
mal and public health consequences of, resistance to flu-
oroquinolones and third-generation cephalosporins, the
Working Group recommends that these drugs should
be reserved for situations where culture and susceptibil-
ity results indicate potential efficacy and when other
antimicrobial agents (eg, doxycycline, amoxicillin) are
not viable options. Moreover, there is no clinical evi-
dence indicating that fluoroquinolones and third-genera-
tion cephalosporins are superior to doxycycline and
amoxicillin in the treatment of chronic bacterial URI in
cats.
Although azithromycin pharmacokinetics have been
determined in cats,48,49 azithromycin and amoxicillin
protocols for the treatment of suspected bacterial upper
respiratory tract infections in shelter cats were equiva-
lent in 1 study where all cats were administered an
antibiotic.43 Azithromycin is also not as efficacious as
doxycycline for the treatment of feline ocular chlamy-
diosis in a study in which all cats were administered an
antibiotic.33 Thus, the Working Group recommends
that azithromycin should be reserved for situations
when chlamydiosis is not likely and when other antimi-
crobial agents (eg, doxycycline, amoxicillin) are not
viable options. Of the 17 reviewers, 16 (94%) agreed
with this recommendation. One reviewer commented
that there is evidence that azithromycin treatment in
people produces therapeutic benefits for infections of
the respiratory tract via mechanisms that are not attrib-
uted to the antibacterial properties.49 However, at this
time, the Working Group does not advocate for the
administration of azithromycin to animals only for its
disease-modifying properties or immunomodulatory
effects.
If Pseudomonas aeruginosa is isolated in pure or
nearly pure culture and believed to be the cause of a
secondary infection, extensive flushing of the nasal cav-
ity under anesthesia should be performed to remove
loculated secretions. Although use of drug combinations
(such as a fluoroquinolone combined with a beta-lactam
[Table 2]) has been recommended to treat P. aeruginosa
infections because of the tendency of this organism to
rapidly develop resistance, monotherapy with a fluoro-
quinolone is accepted for the treatment of P. aeruginosa
otitis/osteomyelitis in human patients, unless resistance
is encountered.50,51 Regardless of whether monotherapy
or combination treatment is chosen, the Working
Group recommends that antimicrobials be selected on
the basis of culture and susceptibility testing and that a
clinical microbiologist, clinical pharmacologist, or inter-
nal medicine specialist with expertise in infectious
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disease be consulted before initiating treatment. Of the
17 reviewers, 15 (88%) agreed with this recommenda-
tion and 2 were neutral (12%).
Optimal duration of the treatment of chronic bacte-
rial URI in cats with no other underlying disease is
unknown. The consensus of the Working Group was to
administer the chosen antimicrobial for at least 7 days
and if the drug is tolerated and showing a positive clini-
cal effect, the drug should be continued as long as there
is progressive clinical improvement and for at least
1 week past clinical resolution of nasal disease or pla-
teau in response to treatment. However, the Working
Group acknowledges that stopping treatment sooner
might also be effective in some cats.
If mucopurulent discharge with or without sneezing
recurs after treatment in a cat that has had a thorough
diagnostic evaluation, the previously effective antimicro-
bial agent is usually prescribed empirically again, for at
least 7–10 days, to assess for the treatment response.
The Working Group recommends avoidance of
repeated empirical treatment on a regular basis when-
ever possible. However, some cats with suspected
chronic bacterial URI require such an approach to les-
sen clinical signs of disease even though clinical cure is
never achieved. The Working Group believes there is
currently no known optimal protocol for repeated
empirical treatment for chronic URI in cats. Evidence
from the human infectious disease literature shows
organisms cultured from patients within 3 months of
primary treatment had a higher likelihood of resistance
to the treatment drug or class used. As such, some res-
piratory treatment guidelines in human medicine recom-
mend a different drug (or drug class) if used within
3 months of the initial treatment.52 Until further data
are available, the Working Group recommends use of
the previously effective antimicrobial drug with switch
to a different drug class or a more active drug within
the class if treatment is ineffective after a minimum of
48 hours. Collection of specimens for culture and sus-
ceptibility is recommended if neither of these
approaches is successful.
There is no evidence to support the use of topical
(intranasal) antiseptic or antimicrobial administration
for the treatment of acute or chronic bacterial URI.
However, topical administration of 0.9% saline solu-
tion is believed to have has a mild mucolytic effect and
might be effective in clearing nasal secretions in some
cats.
Many cats with chronic URTD have complete diag-
nostic evaluations performed and the only finding is lym-
phocytic–plasmacytic or mixed inflammation identified
on histopathological evaluation without a known under-
lying cause (idiopathic feline rhinosinusitis). Although
chronic infection with respiratory viruses has been specu-
lated to play a role in this disease, the true underlying eti-
ology remains enigmatic.16,22 Although there was no
association among Bartonella spp. test results among cats
with and without URTD in shelters in 1 study or with
chronic rhinosinusitis in another study, additional
research is required to ascertain the role of Bartonella
spp. in feline chronic rhinosinusitis.53,54
Monitoring Treatment of Chronic Bacterial Upper
Respiratory Infection
Because results of bacterial culture and antimicrobial
susceptibility testing from specimens collected from the
nasal cavity are difficult to interpret, monitoring the
efficacy of treatment of cats with suspected chronic bac-
terial URI is usually based on clinical signs of disease.
Canine Infectious Respiratory Disease Complex
Definition and Causes
The clinical syndrome associated with CIRDC is gen-
erally characterized by an acute onset of cough with or
without sneezing. Nasal and ocular discharges can also
occur depending on the infectious agent that is
involved. Fever is uncommon but might be present. The
viruses that have been implicated include canine aden-
ovirus 2, canine distemper virus, canine respiratory
coronavirus, canine influenza viruses, canine her-
pesvirus, canine pneumovirus, and canine parainfluenza
virus.55–59 Bacteria implicated as primary pathogens in
this complex include B. bronchiseptica, S. equi sub-
species zooepidemicus, and Mycoplasma spp.55,59–63
Dogs with canine distemper virus infection often have
diarrhea and can have mucopurulent ocular and nasal
discharge that might be confused with mucopurulent
discharges caused by primary bacterial pathogens.
Because of its significance to the health of other dogs
and for prognosis, the possibility of underlying distem-
per virus infection should always be considered in
young dogs with mucopurulent ocular and nasal dis-
charges, even when other signs of distemper are absent.
Infection with S. equi subspecies zooepidemicus should
be suspected if cases of acute hemorrhagic pneumonia
or sudden death are reported.64
Co-infections with multiple respiratory pathogens are
common in dogs with CIRDC and each of the agents
can be harbored by dogs with no clinical signs. Vaccines
are available for some of the causes of CIRDC in some
countries and include canine parainfluenza virus, canine
adenovirus 2, canine distemper virus, H3N8 canine
influenza virus, H3N2 influenza virus, and B. bron-
chiseptica. With the exception of canine distemper virus,
the immunity induced by vaccination does not prevent
colonization and shedding of the organisms and clinical
signs of disease can develop in vaccinated dogs (2011
AAHA Canine Vaccination Guidelines; www.aahanet.
org). However, morbidity is generally decreased in vac-
cinates compared with dogs that are not vaccinated
when exposed to the pathogens.
Diagnosis of Bacterial Causes of CIRDC
A thorough history and physical examination should
be performed on all dogs with suspected CIRDC. Many
diagnostic tests could be performed to assess for evi-
dence of primary or secondary bacterial CIRDC. It is
the opinion of the Working Group that there is limited
benefit to performing cytology of nasal discharges to
diagnose bacterial infection and guide the antimicrobial
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choice. Aerobic bacterial culture and antimicrobial sus-
ceptibility testing, Mycoplasma spp. culture (or PCR
assay), and molecular diagnostic procedures for canine
parainfluenza virus, canine adenovirus 2, canine distem-
per virus, canine respiratory coronavirus, canine influ-
enza viruses, canine herpesvirus, pneumovirus,
B. bronchiseptica, and Mycoplasma spp. (or M. cynos
alone) can be performed. However, each of these organ-
isms can be grown or detected by molecular methods
from healthy and diseased dogs and vaccine strains of
the organisms can be amplified by molecular diagnostic
assays.65 Molecular assays might also be of limited sen-
sitivity by the time dogs are presented for examination
because viral shedding rates tend to peak very early in
disease. Thus, these tests are generally not recom-
mended by the Working Group for single cases with
typical clinical presentations, no evidence of pneumonia,
and when high-risk populations (eg, breeding kennels)
are not involved.
If an outbreak of CIRDC is suspected in populations
of dogs like those in shelters, breeding kennels, board-
ing facilities, or multiple dog households, molecular
assays might be indicated, along with bacterial culture
and serological testing for viral pathogens, particularly
if poor response to treatment or severe clinical disease
is occurring. If possible, specimens from respiratory
discharges should be collected from several affected
dogs and assayed individually to increase sensitivity
and positive predictive value and necropsy should
be performed if there are fatalities. If clinical signs
consistent with pneumonia develop, a more extensive
diagnostic evaluation is indicated (See the Pneumonia
in Dogs and Cats section).
Treatment of Suspected Bacterial Canine Infectious
Respiratory Disease Complex
The majority of cases of CIRDC are currently
believed to be viral in etiology and so antimicrobial
administration is often not indicated. Most dogs with
clinical signs of CIRDC including mucopurulent nasal
discharge maintain normal appetite and attitude and
might resolve spontaneously within 10 days without
antimicrobial treatment. The Working Group recom-
mends that antimicrobial treatment be considered
within the 10-day observation period only if fever,
lethargy, or inappetence is present together with mucop-
urulent discharges.
If bacterial CIRDC is suspected in dogs with mucop-
urulent nasal discharge, fever, lethargy, or inappetence
but no clinical evidence of pneumonia (eg, crackles or
wheezes on thoracic auscultation), the Working Group
recommends administration of doxycycline empirically
for 7–10 days as the first-line antimicrobial option
(Table 1). Doxycycline is believed to have clinical activ-
ity against Mycoplasma. As in cats, doxycycline is well
tolerated by dogs and isolates of B. bronchiseptica from
dogs are typically susceptible in vitro to doxycy-
cline.60,66 However, the susceptibility testing studies
used an unapproved standard. Optimal duration of
treatment for dogs with bacterial causes of CIRDC is
unknown and the 7–10-day recommendation was based
on the clinical experiences of the Working Group. Of
the 17 reviewers, 15 (88%) agreed with this recommen-
dation and 2 disagreed. One reviewer stated that if there
is no evidence of pneumonia and the case is not at high
risk of pneumonia (brachycephalic, collapsing airways;
immunosuppressed), antimicrobial treatment is not indi-
cated at all. The other dissenting reviewer disagreed
with the recommendation because there is no break-
point data for doxycycline for B. bronchiseptica or
Mycoplasma spp. in dogs and so whether the agents are
truly susceptible to the drug is unknown.
Additional antimicrobial susceptibility data for sec-
ondary bacterial agents like Pasteurella spp., Streptococ-
cus spp., Staphylococcus spp., and anaerobes are
needed. For Pasteurella spp. and Streptococcus spp.,
amoxicillin is usually adequate, whereas strains of Sta-
phylococcus spp. are usually susceptible in vitro to
amoxicillin–clavulanic acid. Thus, these antimicrobials
are considered by the Working Group to be alternate
first-line antimicrobials for the treatment of secondary
bacterial infections in this syndrome if treatment with
doxycycline fails or is not possible (eg, it is not well tol-
erated). However, it should also be recognized that
some B. bronchiseptica isolates and all mycoplasmas are
resistant to amoxicillin–clavulanate. Of the 17 reviewers,
13 (77%) agreed, 3 reviewers (18%) disagreed, and 1
reviewer was neutral (6%). Reviewers that provided
negative comments were concerned that because the
concentrations of beta-lactams in bronchial secretions
are unknown for dogs and cats, the use of these drugs
could be ineffective if tracheobronchitis without pneu-
monia was present. Another concern was that use of
amoxicillin–clavulanate more likely selects for resistance
phenotypes of clinical concern (eg, methicillin resistance
in staphylococci).
Inhalational aminoglycoside treatment has been anec-
dotally mentioned as beneficial for the management of
dogs with B. bronchiseptica-associated CIRDC. How-
ever, in the absence of controlled studies for safety or
efficacy, the Working Group does not recommend this
treatment protocol for dogs with suspected bacterial
CIRDC.
Monitoring Treatment of Bacterial Canine Infectious
Respiratory Disease Complex
This disease syndrome is usually self-limited or
responds quickly to antimicrobial treatment. Thus, pri-
mary or repeated diagnostic tests are rarely needed
unless pneumonia is suspected. Bacterial culture is not
recommended after successful treatment. Canine infec-
tious respiratory disease complex has not been associ-
ated with chronic upper respiratory disease in the dogs.
Most dogs with bacterial CIRDC have clinical signs
that resolve quickly and so if the first drug chosen is
ineffective and bacterial disease is still suspected after
the first 7 days, the Working Group recommends that a
more extensive diagnostic workup should be considered
before considering use of other drug classes like fluoro-
quinolones or azithromycin.
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Bacterial Bronchitis in Dogs and Cats
Definition and Causes
Inflammation of the bronchi in dogs and cats is asso-
ciated with many different conditions including inhaled
irritants; infections by bacteria, viruses, Dirofilaria
immitis, respiratory parasites (tissue migration of Toxo-
cara canis); pharyngeal or esophageal dysfunction; and
allergies.67 Acute inflammation of the bronchi can occur
secondary to the primary infectious disease agents dis-
cussed in the acute and chronic URI in cats section and
in CIRDC section. In general, the clinical manifesta-
tions, diagnostic plan, and treatment plan are as
described in those sections. However, some dogs and
cats infected with the primary bacterial pathogens
B. bronchiseptica and Mycoplasma spp. can develop
chronic bronchitis or bronchopneumonia.68 In addition,
dogs and cats with other inflammatory diseases of the
bronchi or anatomic defects of the larynx and trachea
(eg, laryngeal paralysis, collapsing airways) might
develop secondary bacterial bronchitis. The source of
those bacteria is thought to be the natural oral micro-
biota. Thus, the same bacteria described for secondary
bacterial URI in cats and secondary bacterial CIRDC
in dogs might be associated with bronchitis. However,
many dogs with chronic bronchitis do not have large
numbers of bacteria cultured after bronchoalveolar
lavage and so the syndrome is not always associated
with bacterial infection.69,70
Diagnosis of Suspected Bacterial Bronchitis
The primary clinical manifestation of bacterial
bronchitis in dogs and cats is cough, with or without
signs of respiratory distress. Dogs or cats with
chronic cough, with or without prior evidence of URI
or CIRDC should have a full physical examination
performed, which should include thorough tracheal
and thoracic auscultation. Thoracic radiographs
should be made on full inspiration to evaluate for
pulmonary and cardiac changes that could be associ-
ated with cough. In dogs, radiographs should include
the cervical and intrathoracic trachea and both inspi-
ratory and expiratory radiographs can be performed
to identify collapsing airways. Alternately, fluoroscopy
is available in some veterinary clinics for diagnosis of
collapsing airways. Some dogs and cats with bacterial
bronchitis have radiographic evidence of thickened
bronchi, but others have normal radiographs even
though inflammation exists on cytology of airway
washings. Computed tomography can also be used
to determine the extent of disease. Other causes of
bronchial inflammation should be explored (D. immitis
serology, fecal flotation, fecal sedimentation, Baer-
mann test, laryngeal function evaluation) as indicated
by the history.
If radiographic evidence of bronchial disease is pre-
sent or suspected based on clinical findings, airway
washings for cytological examination are indicated to
determine the type of inflammation that is present and
to obtain materials for Mycoplasma spp. culture and
aerobic bacterial culture and antimicrobial susceptibil-
ity testing. Mycoplasma PCR assay results do not
always correlate with those of culture and might reflect
oral contamination.71 Specimens obtained by bron-
choscopy are most accurate for diagnosis, but collec-
tion of specimens by other methods like tracheal
washing is acceptable if diffuse disease is present and
bronchoscopy is not available, not affordable or of too
great a risk to the animal. The results of analysis of
bronchoalveolar lavage and brush specimens are not
always in agreement.72
The presence of neutrophilic inflammation, intracellu-
lar bacteria, and positive bacterial culture with charac-
teristic radiographic findings suggests primary or
secondary bacterial bronchitis. However, the trachea is
not sterile in normal dogs and low numbers of bacteria
cultured in the absence of cytological evidence of intra-
cellular bacteria might not imply bacterial infection.
Treatment of Suspected Bacterial Bronchitis
While waiting for results of culture and antimicro-
bial susceptibility testing, the Working Group recom-
mends either no antimicrobial treatment or, if the
clinical disease is severe, empirical administration of
doxycycline for 7–10 days (Tables 1 and 2). The use of
doxycycline is recommended based on its in vitro activ-
ity against B. bronchiseptica isolates from dogs and
cats,31,66,73 reports of positive clinical responses to
doxycycline in cats with respiratory Mycoplasma infec-
tions, and a low rate of adverse effects.74,75 Of the 17
reviewers, 16 (94%) agreed with this Working Group
recommendation and 1 disagreed because there is no
breakpoint data for this antimicrobial drug for these
bacteria in dogs. Depending on the clinical and labora-
tory testing results, antimicrobial treatment is contin-
ued, initiated, or modified based on antimicrobial
susceptibility testing with the drug that is selected
being one believed to penetrate the blood bronchus
barrier based on data from other species. If a positive
response is obtained in the first 7–10 days, treatment
should be continued to 1 week past resolution of clini-
cal signs of disease. Optimal duration of treatment for
this syndrome is unknown and so this recommendation
was based on the experiences of the clinicians on the
Working Group. Dogs that fail to respond to antimi-
crobial treatment are likely to have primary chronic
(noninfectious) bronchitis.
Most veterinary microbiology laboratories do not
report antimicrobial susceptibility results for Myco-
plasma spp. and this genus can be difficult to culture.
Thus, the antimicrobial choices for dogs with suspected
or proven Mycoplasma-associated bronchitis are often
made empirically. Doxycycline or minocycline is com-
monly used by veterinarians for this syndrome and is
likely to have a therapeutic effect for pets with sus-
pected Mycoplasma spp. bronchitis.68,76 Veterinary fluo-
roquinolones and azithromycin are other drugs that
might be effective for the treatment of Mycoplasma spp.
infections.
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Monitoring Treatment of Bacterial Bronchitis
If bronchitis is associated with Mycoplasma spp. or
B. bronchiseptica, clinical resolution might be obtained
with 1 course of antimicrobial treatment. In some cases,
prolonged antimicrobial treatment might be needed. In
the event that another primary cause of inflammation
such as allergic bronchitis exists and secondary bacterial
infections are occurring, recurrent treatment might be
required. Controlling inflammation associated with the
primary disease syndrome might also lessen recurrence
of secondary bacterial bronchitis.77 Repeated thoracic
radiographs can be taken to follow bronchial changes,
but this is of limited sensitivity. In some cases, repeated
cytology and culture might be indicated.
Pneumonia in Dogs and Cats
Definition and Causes
Inflammation of the lungs (pneumonia) can occur
after a variety of insults. In dogs and cats, although
uncommon, primary bacterial pneumonia can occur
after infection with B. bronchiseptica, Mycoplasma
spp., S. equi zooepidemicus, S. canis, and Yersinia
pestis.61–64,68,78–80 Of 65 puppies <1 year of age with
“community acquired” pneumonia in the United States,
49% were infected with B. bronchiseptica.80 Dogs with
B. bronchiseptica infection were younger and had more
severe disease than dogs from which other bacteria were
cultured. Most cases of bacterial pneumonia in dogs
and cats are secondary to other primary inflammatory
events like viral infections or aspiration of oral, esopha-
geal, or gastric contents during vomiting or regurgita-
tion (commonly associated with megaesophagus), after
aspiration because of pharyngeal or laryngeal function
abnormalities, during anesthesia recovery, and after
inhalation of foreign bodies.81–83 In addition, bacterial
pneumonia can develop in the presence of immunodefi-
ciency syndromes. Secondary bacterial pneumonia
potentially could develop as a result of other pulmonary
or airway diseases like neoplasia, ciliary dyskinesia,
bronchiectasis, and collapsing airways.
Common organisms isolated from dogs and cats with
lower respiratory disease include E. coli, Pasteurella
spp., Streptococcus spp, B. bronchiseptica, Enterococcus
spp., Mycoplasma spp., S. pseudintermedius and other
coagulase-positive Staphylococcus spp., and Pseu-
domonas spp.78–80,84–87
Diagnosis of Bacterial Pneumonia
Dogs and cats that develop cough that is associated
with fever, lethargy, inappetence, or tachypnea should
be evaluated for the presence of pneumonia by a full
physical examination, complete blood cell count, and
thoracic radiographs. If clinicopathologic findings and
thoracic radiological findings (alveolar lung disease)
support a diagnosis of bacterial pneumonia, collection
of a transtracheal, endotracheal, or a bronchoalveolar
lavage specimen for cytologic examination, aerobic
bacterial culture, and antimicrobial susceptibility and
Mycoplasma spp. culture is recommended.
Culture and susceptibility testing should be recom-
mended to the client and performed before starting
antimicrobial drug treatment, provided that the animal is
sufficiently stable; however, antimicrobial treatment
should not be unduly delayed. Although no controlled
data are available for dogs and cats, the clinical opinion
of the Working Group is that antimicrobial treatment
should be initiated as soon as possible and within
1–2 hours if clinical signs of sepsis exist.
In addition, not all cases of aspiration pneumonia
require antimicrobial treatment, because clinical disease
might be primarily or solely chemical pneumonitis from
aspirated materials. Anaerobic bacteria are sometimes
associated with pneumonia, particularly if there is a his-
tory of aspiration, or grass awn foreign bodies are pre-
sent. However, some commercial laboratories have
difficulty culturing these agents and most do not pro-
vide antimicrobial susceptibility data; thus, antimicro-
bial agents with an anaerobic spectrum are often
included for the treatment of bacterial pneumonia in
dogs and cats when anaerobic culture is not available
or likely to be reliable.
In cases with probable aspiration pneumonia, multi-
ple bacteria are often cultured making it difficult to
determine which is involved with continued inflamma-
tion. Care should also be exercised when interpreting
the significance of few or rare organisms, mixed culture,
or presence of possible airway contaminants such as
coagulase-negative staphylococci or Bacillus spp. If an
endoscope is used to collect a lavage specimen, the pos-
sibility of endoscope-related contamination should also
be considered, particularly when unusual species such
as Serratia or Stenotrophomonas are isolated.88
The Working Group recommends consulting with a
clinical microbiologist or specialist with expertise with
infectious diseases or pulmonology for interpretation of
culture and antimicrobial susceptibility results from
endotracheal or bronchoalveolar lavage specimens. Fif-
teen reviewers (88%) agreed, 1 disagreed (6%), and 1
(6%) was neutral to this Working Group recommenda-
tion. The person that disagreed believes that a consulta-
tion is only needed for difficult cases.
Because bacterial pneumonia is often associated with
an underlying disease process, attempts to identify and
manage current problems should be made. In cats and
dogs that have life-threatening bacterial pneumonia or
are oxygen dependent, airway sampling might not be
feasible. Although more data are required to clarify the
usefulness of blood cultures (aerobic and anaerobic) in
animals with severe pneumonia, it is the consensus
opinion of the Working Group to consider blood cul-
tures in these animals before starting empirical antimi-
crobial drug treatment as an alternative way to obtain
isolates for targeted antimicrobial susceptibility to guide
long-term management. Empirical antimicrobial treat-
ment should not be delayed in an effort to stabilize
affected animals and obtain a pre-antimicrobial airway
sample. Thirteen reviewers (82%) agreed, 3 were neutral
(18%), and 1 (6%) disagreed with this Working Group
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recommendation. The primary comment was that blood
culture for this purpose in children is known to be
insensitive and false-positive results can be obtained.89
Treatment of Suspected Bacterial Pneumonia
The Working Group discussed whether antimicrobial
treatment should be delayed while waiting until the
results of culture and antimicrobial susceptibility testing
are available. However, as not all clients can afford the
diagnostic procedures and pneumonia can be a life-
threatening disease, the consensus opinion was to pro-
vide empirical antimicrobial treatment while waiting for
test results with potential for de-escalation of treatment
based on antimicrobial susceptibility testing. While hos-
pitalized, parenteral antimicrobial treatment is generally
recommended by the Working Group for the treatment
of animals with pneumonia, regardless of the severity of
disease. Once the animal is discharged, treatment can
be continued by means of the oral route. It is the opin-
ion of the Working Group that doxycycline is a reason-
able empiric choice for dogs or cats with mild
pneumonia that is suspected to be from infection with
B. bronchiseptica or Mycoplasma spp. (eg, the animal is
from a shelter or boarding environment) and no other
systemic signs of disease like fever, dehydration,
lethargy, or respiratory distress are present. This is
based on the known susceptibility of these organisms to
doxycycline (see Section on Canine Infectious Respira-
tory Disease Complex) and published case reports of
successful treatment with doxycycline (Table 2).74,75,78
Fifteen reviewers (88%) agreed and 2 (12%) disagreed
with this Working Group recommendation. One
reviewer stated that they doubted that pneumonia
would be present without fever and if pneumonia exists,
it should be treated with bactericidal drugs. The other
dissenting reviewer commented on the lack of break-
point data for doxycycline and the bacteria from dogs
and cats as well as the concern that doxycycline might
not penetrate into the extracellular fluids of the lungs.
Azithromycin is used by some veterinarians empiri-
cally in dogs with uncomplicated pneumonia, but the
Working Group believes that data supporting this rec-
ommendation are lacking.
Streptococcus equi subspecies zooepidemicus strains
isolated from dogs are susceptible to penicillin, amoxi-
cillin, and ampicillin. Administration of amoxicillin–
clavulanate is unnecessary if this organism is suspected
because streptococci are not known to produce
beta-lactamases.90
Not all dogs or cats with acute aspiration pneumonia
have a bacterial infection. However, aspirated bacteria
can cause infection secondary to the chemical inflamma-
tion associated with aspiration. If the dog or cat is
acutely affected and has no evidence of systemic sepsis,
the Working Group believes that either no treatment or
parenteral administration of a beta-lactam antimicrobial
like ampicillin, ampicillin-sulbactam, or the first-genera-
tion cephalosporin cefazolin might be sufficient
(Table 2). Thirteen reviewers (82%) agreed, 3 were neu-
tral (18%), and 1 (6%) disagreed with this Working
Group recommendation. The primary comments were
that the risk of not treating a case was greater than the
perceived benefit of withholding treatment or that oral
medications could be adequate for this syndrome. How-
ever, if megaesophagus or other esophageal motility dis-
orders exist, parenteral administration of the
antimicrobial drug is indicated.
If clinical findings in dogs or cats with pneumonia
suggest the existence of sepsis (eg, injected mucous
membranes, hypoglycemia), the Working Group recom-
mends concurrent parenteral administration of either
enrofloxacin or marbofloxacin (available in injectable
form in some countries) combined with a drug with
Gram-positive and anaerobic spectra until bacterial cul-
ture and antimicrobial susceptibility testing results
return. In 1 study, most bacteria from the lower airways
of dogs with respiratory disease were susceptible to
enrofloxacin.91 Other drugs for parenteral use with a
Gram-negative spectrum might be indicated in lieu of
enrofloxacin based on culture and antimicrobial suscep-
tibility testing (Table 2). The Working Group states
that common options for Gram-positive and anaerobic
bacteria include ampicillin or clindamycin administered
parenterally (Table 2). Which of these drugs to choose
while waiting on antimicrobial susceptibility test results
will depend on the most likely infectious agent sus-
pected, previously prescribed antimicrobials (if any),
and historical antimicrobial resistance in the geographi-
cal region. Fourteen reviewers (82%) agreed and 3
(18%) disagreed with this Working Group recommen-
dation. The primary comment was that if Bacteroides
spp. were present, clindamycin could be ineffective and
that metronidazole could be considered another option.
Drugs that could be administered PO for outpatient
treatment of bacterial pneumonia should be selected on
the basis of culture and antimicrobial susceptibility
results for organisms isolated from the lower airways,
de-escalating whenever possible. If culture and antimi-
crobial susceptibility testing was not performed, the
antimicrobial drug class or classes that were initially
prescribed and associated with clinical response is/are
chosen for continued oral treatment.
Inflammatory responses to bacterial pneumonia
increase pulmonary pathology. Thus, glucocorticoids are
used concurrently in some human patients with bacterial
pneumonia.92,93 However, it was the consensus opinion
of the Working Group that further data are needed from
dogs and cats before a definitive recommendation can be
made in regard to the use of systemic or inhaled gluco-
corticoids, which have the potential to contribute to
adverse outcomes due to immunosuppression.
Monitoring Treatment of Bacterial Pneumonia
The current recommendation in most veterinary text-
books is to treat bacterial pneumonia for 4–6 weeks,
but evidence to support this duration of treatment in
either cats or dogs is lacking. Although such lengthy
courses of antimicrobial treatment might be necessary
for some animals with severe pulmonary involvement or
those with immunodeficiency syndromes, it is the
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consensus opinion of the Working Group that shorter
courses of appropriate treatment, such as those used to
treat pneumonia in humans, might be effective in some
situations. In the face of insufficient data supporting a
shorter course of treatment, the Working Group recom-
mends re-evaluation of animals with pneumonia no
later than 10–14 days after starting treatment. At that
point, decisions to extend treatment should be based on
clinical, hematological, and radiographic findings. Addi-
tional studies evaluating durations of treatment that are
shorter than 4–6 weeks are required.
Pyothorax in Dogs and Cats
Definition and Causes
In cats with pyothorax, the bacteria isolated from
thoracic fluid are most commonly a mixture of oropha-
ryngeal anaerobes including Fusobacterium, Prevotella,
Porphyromonas, Bacteroides, Peptostreptococcus,
Clostridium, Actinomyces, and Filifactor villosus. Pas-
teurella spp, Streptococcus spp., and Mycoplasma spp.
have also been isolated.94–97 Less commonly, Staphylo-
coccus spp., Gram-negative bacteria other than Pas-
teurella, and organisms such as Nocardia spp. and
Rhodococcus equi have been isolated. Wounds resulting
from cat fights and URI are risk factors for pyothorax
in cats.97
Bacteria isolated from dogs with pyothorax are most
commonly mixed anaerobes (Prevotella spp., Peptostrep-
tococcus spp., Propionibacterium acnes, Clostridium spp.,
Bacteroides spp., Fusobacterium spp.) and Enterobacte-
riaceae, especially E. coli and Klebsiella pneumo-
niae.94,98–100 Streptococcus canis, Staphylococcus spp,
Enterococcus spp., Corynebacterium spp., Bacillus spp.,
Trueperella (formerly Arcanobacterium) pyogenes, Pas-
teurella, Acinetobacter, Capnocytophaga spp., Enterobac-
ter spp., Stenotrophomonas maltophila, Aeromonas
hydrophila, Achromobacter xylosoxidans, Serratia mar-
cescens and Pseudomonas spp. Actinomyces spp. and to
a lesser extent Nocardia spp. and Streptomyces spp.
have been implicated in canine pyothorax.99 Pyothorax
in dogs commonly results from migrating plant foreign
bodies or trauma but can also result from bite wound
inoculation.94,98–103
Diagnosis of Pyothorax in Dogs and Cats
Thoracic radiographs should be made to evaluate for
the presence of lung consolidation in the dog or cat
after therapeutic thoracocentesis. A pleural fluid speci-
men should be submitted for cytologic analysis, aerobic
bacterial culture, and antimicrobial susceptibility test-
ing, as well as culture for anaerobic bacteria and Myco-
plasma spp. (cats) if available. Performance of Gram
stain and acid-fast stains might provide addition infor-
mation. Detection of actinomycetes and Mycoplasma
spp. requires specialized growth conditions and pro-
longed incubation, and so the laboratory should be
informed that Actinomyces spp., Nocardia spp., or
Mycoplasma spp. are differential diagnoses.
Treatment of Pyothorax in Dogs and Cats
The Working Group recommends that treatment of
pyothorax include IV fluid administration and critically,
drainage of pus after placement of chest tubes with
intermittent or preferably continuous suction with or
without lavage.96–103 Surgical debridement might be
required in some cases. Sixteen reviewers (94%) agreed,
and 1 (6%) disagreed with this Working Group recom-
mendation. The primary comment was that evidence
supporting the definitive need for thoracic lavage was
lacking. However, based on lack of data supporting its
use, the Working Group does not recommend adminis-
tration of antimicrobial drugs into the pleural space.
The Working Group recommends the combination of
parenteral administration of enrofloxacin or mar-
bofloxacin (when available in parenteral form) with a
penicillin or clindamycin combined with therapeutic
drainage of the pleural space with or without lavage for
the initial treatment or canine and feline pyothorax
pending the results of culture and antimicrobial suscepti-
bility testing. Sixteen reviewers (94%) agreed and 1 (6%)
disagreed with this Working Group recommendation.
The primary comment was that pradofloxacin adminis-
tered PO as a single drug could be effective if available.
Treatment with an antimicrobial drug with activity
against anaerobes should be continued regardless of cul-
ture results because fastidious anaerobic bacteria could
be present. If combination treatment was initiated and
the bacterial isolates are susceptible to both drugs in
the initial treatment regime, then either of the treatment
drugs could be discontinued. If organisms are grown
that are resistant to one of the drugs and clinical
improvement is not noted, that antimicrobial agent
should be discontinued. A second drug to which the iso-
late is susceptible should be substituted if the animal
has not responded sufficiently. If organisms are grown
that are resistant to both antimicrobials or clinical evi-
dence of improvement is not evident, antimicrobial
treatment should be changed to a drug to which the
organisms are susceptible in vitro. Fifteen reviewers
(88%) agreed, 1 was neutral (6%), and 1 (6%) dis-
agreed with this Working Group recommendation. The
dissenting reviewer stated that mixed culture results can
be difficult to interpret and so if the animal’s clinical
condition improves on the first therapeutic regimen,
changes should not be made.
Consultation with a specialist is recommended when
multidrug-resistant organisms are isolated. In all situa-
tions, the clinical condition must be considered when
interpreting culture results, and continuing apparently
effective treatment despite in vitro resistance is recom-
mended because of the potential that the offending
organism was not isolated.
Monitoring Treatment of Pyothorax
It has been recommended that cats with pyothorax
be treated for a minimum of 3 weeks and ideally 4–
6 weeks.97,101 Additional research is required to deter-
mine whether shorter periods of antimicrobial drug
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treatment might be adequate. Serial thoracic radiogra-
phy might be useful to determine whether antimicro-
bial treatment needs to be continued, although further
study is also required to determine whether persistent
radiographic abnormalities correlate with the need for
additional antimicrobial drug treatment. At a mini-
mum, follow-up radiography should be performed for
10–14 days after starting treatment and at completion
of treatment. If the pyothorax persists or reoccurs
after cessation of antimicrobials, repeated thoracocen-
tesis should be performed for cytological assessment
and for culture and antimicrobial susceptibility testing.
Conclusions
The Working Group emphasizes the need for addi-
tional prospective studies to evaluate different treat-
ments and treatment durations in dogs and cats with
bacterial respiratory diseases so that more accurate rec-
ommendations can be made. For the same purpose,
research is needed to develop standard practices for col-
lection of clinical specimens and interpretation of cul-
ture results.
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